AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: BIAF
Report Date: 2026-04-09
Full Report: https://amaly.io/stock/BIAF

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: This report evaluates the Shariah compliance of bioAffinity Technologies, Inc. (BIAF), a biotechnology company focused on cancer diagnostics. Financial ratios indicate strong performance in debt and non-permissible income metrics, but the interest income ratio fails thresholds across standards. Business activities in medical diagnostics are permissible, with no non-compliant revenue sources identified. Index inclusion research shows no presence in major Shariah indices due to micro-cap status. Overall, the company requires purification for trace non-compliant income and ongoing monitoring for financial stability.

Primary Compliance Concerns:
- Interest income ratio of 0.80% fails the 5% threshold across AAOIFI, MSCI, and S&P standards
- Historical revenue anomalies (e.g., zero revenue in FY2022 leading to inflated ratios) raise data reliability concerns
- Micro-cap status excludes from Shariah indices despite passing core financial screens

Purification Requirement: 0.80%
Index Inclusion: Not included in any major Shariah indices (S&P, MSCI, FTSE, DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 19.9%
Liquidity Ratio: 6.6%
Interest Income Ratio: 0.0%
Purification Required: 0.80%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: INCLUDED
MSCI Islamic: INCLUDED
DJIM: INCLUDED
FTSE Shariah: INCLUDED
Total: 4 of 4
Last Verified: 2026-01-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-27T12:00:00Z

---
Full interactive report: https://amaly.io/stock/BIAF
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.